Answers are grounded in this paper and cite their sources.
Guselkumab is a highly effective, well-tolerated, maintenance therapy, including in adalimumab nonresponders.
No takes yet. Share an insight, caveat, or question.
Reich et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: